BIOGEN INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 230.6 USD | +0.23% |
|
+4.09% | -10.90% |
| May. 16 | Sector Update: Health Care Stocks Mixed in Late Afternoon Trading | MT |
| May. 16 | Sector Update: Health Care Stocks Ease Thursday Afternoon | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 9.52B | Sales 2025 * | 9.55B | Capitalization | 33.57B |
|---|---|---|---|---|---|
| Net income 2024 * | 1.9B | Net income 2025 * | 2.21B | EV / Sales 2024 * | 3.84 x |
| Net Debt 2024 * | 3.01B | Net Debt 2025 * | 536M | EV / Sales 2025 * | 3.57 x |
| P/E ratio 2024 * |
17.8
x | P/E ratio 2025 * |
15.4
x | Employees | 7,570 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.81% |
More Fundamentals
* Assessed data
More news
Latest transcript on Biogen Inc.
More recommendations
More press releases
More news
| 1 day | +0.23% | ||
| 1 week | +4.09% | ||
| Current month | +7.33% | ||
| 1 month | +19.99% | ||
| 3 months | +5.24% | ||
| 6 months | +1.13% | ||
| Current year | -10.90% |
1 week
221.72
236.90
1 month
189.44236.90
Current year
189.44268.30
1 year
189.44319.76
3 years
187.16468.55
5 years
187.16468.55
10 years
187.16480.18
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 64 | 22-11-13 | |
| Director of Finance/CFO | 60 | 20-08-14 | |
Nicole Murphy
COO | Chief Operating Officer | - | 14-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Stephen Sherwin
BRD | Director/Board Member | 75 | 09-12-31 |
William Hawkins
BRD | Director/Board Member | 70 | 19-06-18 |
Caroline Dorsa
CHM | Chairman | 64 | 10-01-02 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 4.30% | 1 M€ | +0.15% | - | |
| 3.92% | 0 M€ | 0.00% | - | |
| 3.75% | 0 M€ | 0.00% | - | |
| 2.39% | 13,519 M€ | +7.14% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-17 | 230.6 | +0.23% | 985,059 |
| 24-05-16 | 230 | -2.24% | 936,678 |
| 24-05-15 | 235.3 | +3.72% | 1,792,660 |
| 24-05-14 | 226.9 | +0.68% | 1,126,999 |
| 24-05-13 | 225.3 | +1.73% | 1,274,672 |
Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm EDT
More quotes
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
Pharmaceuticals
Calendar
2024-06-20
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
230.6
USD
Average target price
285.9
USD
Spread / Average Target
+24.01%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -10.90% | 33.57B | |
| -2.32% | 90.45B | |
| +3.68% | 41.45B | |
| -19.56% | 14.73B | |
| -9.06% | 12.82B | |
| -11.34% | 11.7B | |
| -43.53% | 11.44B | |
| +3.75% | 8.79B | |
| -6.32% | 8.35B | |
| -9.24% | 6.86B |
- Stock Market
- Equities
- BIIB Stock
